At Rigel Pharmaceuticals, our purpose is to discover, develop and provide novel therapies.
In particular, we are focused on hematologic disorders and cancer. We see great opportunity to help patients who have diseases where few or no approved treatment options exist.
Rigel’s FDA approved products:
As of June 2026, Rigel has global licensing rights to develop, manufacture and commercialize VEPPANU™ (vepdegestrant), an oral PROteolysis TArgeting Chimera (PROTAC) that is FDA-approved for adults with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), estrogen receptor 1 (ESR1)-mutated advanced or metastatic breast cancer as detected by an FDA-authorized test with disease progression following at least one line of endocrine therapy. Rigel expects VEPPANU will become commercially available in August of 2026.
Rigel works with partners to bring our products to markets outside of the U.S. We also explore new opportunities to expand our product and development pipeline through strategic collaborations that align with our commitment to bring new therapies to patients with unmet medical needs.
Our clinical programs include an interleukin receptor-associated kinase 1 and 4 (IRAK1/4) inhibitor that is currently being evaluated in a Phase 1b study in patients with lower-risk myelodysplastic syndrome.
TAVALISSE Full Prescribing InformationREZLIDHIA Full Prescribing Information, including Boxed WARNING
GAVRETO Full Prescribing Information, including Boxed WARNING
VEPPANU Full Prescribing Information